http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013107659-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4436 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 |
| filingDate | 2011-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013107659-A |
| titleOfInvention | KASEINKINASE INHIBITOR 1δ AND KASEINKINASE 1ε |
| abstract | 1. An oxazolone derivative represented by the following general formula (1): wherein X is a halogen atom (which may be an atom selected from a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom) .2. The oxazolone derivative according to claim 1, wherein the compound of general formula (1) is any of: 4 - ((6-methoxy-3-pyridinyl) methylene) -2- (5-fluoro-2-thienyl) -5 (4H) -oxazolone; 4 - ((6-methoxy-3-pyridinyl) methylene) -2- (5-chloro-2-thienyl) -5 (4H) -oxazolone; 4 - ((6-methoxy-3-pyridinyl) methylene ) -2- (5-bromo-2-thienyl) -5 (4H) -oxazolone and 4 - ((6-methoxy-3-pyridinyl) methylene) -2- (5-iodo-2-thienyl) -5 (4H ) -oxazolone. 3. Casein kinase 1δ inhibitor and casein kinase 1ε inhibitor containing, as an active ingredient, the oxazolone derivative according to claim 1 or 2, its salt, their solvate or their hydrate. 4. A pharmaceutical composition for treating diseases with pathological conditions associated with activation of casein kinase 1δ or casein kinase 1ε, containing, as an active ingredient, the oxazolone derivative according to claim 1 or 2, a salt thereof, a solvate thereof or a hydrate thereof. 5. The pharmaceutical composition of claim 4, wherein the disease is circadian rhythm disorder, including sleep disorder. The pharmaceutical composition of claim 4, wherein the disease is a neurodegenerative disease. The pharmaceutical composition of claim 4, wherein the disease is cancer. A method for treating diseases with pathological conditions associated with activation of casein kinase 1δ or casein kinase 1ε, comprising administering to a patient a pharmaceutical composition containing, as an active ingredient, the oxazolone derivative according to claim 1 or 2, a salt thereof, a solvate thereof or a hydrate thereof. The method of claim 8, wherein the disease is a circadian disorder |
| priorityDate | 2010-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.